Involved Nodal Irradiation vs Involved Field Irradiation After Cth in Ttt of Early Stages HDs
1 other identifier
observational
50
0 countries
N/A
Brief Summary
determine the early toxicity and loco-regional control comparing outcome of radiothrapy rither by using INRT or IFRT in treatment of early stage hodgkin lymphoma determine progression-free survival and late toxisty
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2022
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 9, 2022
CompletedFirst Posted
Study publicly available on registry
March 17, 2022
CompletedStudy Start
First participant enrolled
May 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2025
CompletedMarch 17, 2022
March 1, 2022
2.4 years
March 9, 2022
March 9, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Comparison between different irradiation modalities in tretment of early stage hodgkin lymphoma
involved nodal Irradiation versus Involved field Irradiation after Chemotherapy in treatment of Early stage Hodgkin's lymphoma
baseline
Interventions
involved field irradiation versus nodal field irradiation
Eligibility Criteria
statistical analyses were performed using IBM SPSS Statistics version 20 (SPSS Inc., Chicago, IL, USA). Categorical data were presented as frequencies and percentages, while Chi-square test was used for comparisons between groups. Continuous data were reported as means ±standard deviations and students' T-test was used for comparisons between groups. For comparison between progression free survival ,Kaplan-Mayar survival curve and log-rank test were performed. In all statistical tests p-value \<0.05 was considered statistically significant. •Sample size: All pt who met at inclusion criteria at SECI will be included in our study
You may qualify if:
- Clinical stage I or II, only supra-diaphragmatic nodes, both favorable and unfavorable prognostic subsets
- Previously untreated.
- Age: between 18 and 75 years.
- Good general condition(WHO performance status 0-2).
- Free of concurrent disease.
You may not qualify if:
- Patients with impaired heart, lung, liver, or kidney function.
- Previous malignant diseases or HIV-positive status
- Patient with advanced or infra-diaghragmatic Hodgkin's disease
- Pregnant or lactating women
- Patient with prior irradiation to the neck and thorathic region
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Marwa Esam Eldin
Study Record Dates
First Submitted
March 9, 2022
First Posted
March 17, 2022
Study Start
May 1, 2022
Primary Completion
October 1, 2024
Study Completion
October 1, 2025
Last Updated
March 17, 2022
Record last verified: 2022-03